Sinopharm Group Co., Ltd. Class H 1099
HKEX · Hong Kong SAR China · Distribution Services
HKD 14.86+0.12 (+0.81%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Sinopharm Group (SEHK:1099) has entered into a mutual NDA with Woori IO to explore noninvasive glucose monitoring technology in China. The agreement centers on potential commercialization of Woori IO's technology for diabetes care in the Chinese market. The collaboration may lead to further clinical development and potential global trials if progress continues. For investors tracking healthcare in China, this move positions Sinopharm Group, a major pharma and healthcare distributor, closer...
OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China. This announcement is being made in accordance with Regulation FD to ensure b
BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into ...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.